Efficacy of pembrolizumab in advanced cancer of the vulva: a systematic review and single-arm meta-analysis.

ABSTRACT:

Introduction

Vulvar cancer carries a favourable prognosis in early stages. However, therapeutic options for advanced or recurrent cases are limited despite a variety of therapeutic modalities, such as extensive surgical resection, chemotherapy, and radiotherapy. The most important emerging treatment modalities are immune checkpoint inhibitors. This systematic review and meta-analysis aims to assess the efficacy and safety of pembrolizumab, an immune checkpoint inhibitor, in women with advanced vulvar cancer.

Materials and methods

Following a comprehensive search, review, and appraisal, two relevant single-arm studies were included. Meta-analysis was conducted using R4.3.0 software and RStudio 2023.03.0, presenting the overall effect size with a 95% confidence interval. Heter

SUBMITTER: Schwab R 

PROVIDER: S-EPMC10910062 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature